Genezen has opened its new process development and analytical lab for viral vector production. Genezen, a cell and gene therapy contract development and manufacturing organization, has officially ...

Cell and gene therapies offer hope for previously untreatable diseases, with viral vectors currently favored as the primary gene delivery method. To meet patient needs, reliable and cost-effective ...

Enhancing Scale-Up, Increasing Quality, and Reducing Costs for AVs, LVVs, AAVs and More The 3rd Viral Vector Process Development and Manufacturing Summit returns to Boston, uniting industry leaders ...

Induced pluripotent stem cells, the workhorse of many regenerative medicine projects, start out as differentiated cells that are reprogrammed to pluripotent stem cells by exposure to a complex set of ...

Effective process development for viral vector-based medicines is paramount for optimized process efficiency, robustness, scalability, and product quality. Well-designed processes streamline ...

Intensified methods of viral vector manufacture and development of novel analytical methods for viral vector characterization. Collaborations with industrial and academic partners to further develop ...

The company announced plans to expand its viral vector process development facilities in the United States and its cleanroom facilities in the Netherlands for vector-based products. On Oct. 16, 2017, ...